Trials / Completed
CompletedNCT03035591
ODM-207 in Patients With Advance Solid Tumours
Safety and Pharmacokinetics of ODM-207 in Patients With Selected Advanced Solid Tumours: an Open-label, Non-randomised, Uncontrolled, Multicentre, First-in-human Study With Cohort Expansion
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Orion Corporation, Orion Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a first-in-man study to assess the safety and tolerability and to characterise the pharmacokinetics of ODM-207.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ODM-207 |
Timeline
- Start date
- 2016-12-22
- Primary completion
- 2019-05-10
- Completion
- 2019-05-10
- First posted
- 2017-01-30
- Last updated
- 2019-10-15
Locations
1 site across 1 country: Finland
Source: ClinicalTrials.gov record NCT03035591. Inclusion in this directory is not an endorsement.